Table 39Study characteristics and association between OC use and endometrial cancer mortality

StudyStudy DetailsPoint Estimate (95% CI)aDuration of UsePoint Estimate (95% CI)bCovariatesRegionStudy QualityMeta-Analysis Codec
Cohort
Hannaford, 201033Royal College of General Practitioner's Oral Contraception study
Exposed: 28,806
Unexposed: 17,306

Mean age at entry: 29 yr (SD 6.6)
Recruitment period: 1968–NR
0.43 (0.21 to 0.88)< 4 yr0.9 (0.3 to 2.5)Age, parity, smoking, social classUKFair1
4–8 yrNot calculable
≥ 8+ yr0.2 (0.0 to 1.0)
Vessey, 2010165Women aged 25–39 yr in Oxford Family Planning Association Contraceptive Study
602,700 person-yr (total for exposed and unexposed)

Recruitment period: 1968–1974
0.3 (0.1 to 0.8)< 48 mo0.42 (0.05 to 3.45)Age, parity, BMI, smoking, social classUKFair1
49–96 moNot calculable
≥ 97 moNot calculable

BMI = body mass index; CI = confidence interval; NA = not applicable; NR = not reported; OC = oral contraceptive; OR = odds ratio; UK = United Kingdom; U.S. = United States; yr = year/years

a

Point estimate for meta-analysis of ever versus never OC use.

b

Point estimate for meta-analysis of duration of OC use.

c

Meta-analysis code: 1 = Met inclusion criteria for possible meta-analysis.

Point estimate for meta-analysis of ever versus never OC use.

Point estimate for meta-analysis of duration of OC use.

Meta-analysis code: 1 = Met inclusion criteria for possible meta-analysis.

From: 3, Oral Contraceptives and Other Cancers

Cover of Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer
Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer.
Evidence Reports/Technology Assessments, No. 212.
Havrilesky LJ, Gierisch JM, Moorman PG, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.